Published in Cardiovasc Res on September 01, 1975
Development of a severe model of early coronary artery ligation-induced dysrhythmias in the anaesthetized rat. Br J Pharmacol (1981) 1.24
The role of cyclic adenosine monophosphate in adrenergic effects on ventricular vulnerability to fibrillation in the isolated perfused rat heart. J Clin Invest (1978) 0.89
The effect of hypoxic myocardial preconditioning is highly dependent on the light-dark cycle in Wistar rats. Exp Clin Cardiol (2008) 0.77
Blood cardioplegia delivery. Deleterious effects of potassium versus lidocaine. Ann Surg (1983) 0.77
Carbachol and dibutyryl cyclic GMP on the vulnerability to ventricular fibrillation in rat isolated hearts. Br J Pharmacol (1985) 0.75
Chronophysiological view on changes of the electrical stability of the heart and heart rate under pentobarbital sodium and ketamine/xylazine anesthesia in a hypoventilation-reoxygenation rat model. Exp Clin Cardiol (2004) 0.75
The effect of heart rate on the termination of electrically induced ventricular fibrillation in the isolated perfused rat heart. Basic Res Cardiol (1989) 0.75
The effect of calcium concentration on spontaneous ventricular defibrillation and VF threshold. Basic Res Cardiol (1987) 0.75
The effects of lidocaine on the ventricular fibrillation threshold and primary ventricular fibrillation following acute experimental coronary occlusion. Basic Res Cardiol (1981) 0.75
Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet (1983) 1.91
Lupus anticoagulant in pregnancy. Br J Obstet Gynaecol (1984) 1.30
Characterization of the "border zone" in acute regional ischemia in the dog. Am J Cardiol (1977) 1.28
Biochemical aspects of arrhythmogenesis and ventricular fibrillation. Am J Cardiol (1979) 1.18
Antihypertensive actions of diuretics. Comparative study of an aldosterone antagonist and a thiazide, alone and together. JAMA (1968) 1.16
Effects of substrates on tissue metabolic changes in the isolated rat heart during underperfusion and on release of lactate dehydrogenase and arrhythmias during reperfusion. Circ Res (1978) 1.16
Protective action of amiodarone against ventricular fibrillation in the isolated perfused rat heart. Am J Cardiol (1979) 1.13
Cerebral and valve lesions in SLE: association with antiphospholipid antibodies. J Rheumatol (1988) 1.07
Effects of free fatty acid and enzyme release in experimental glucose on myocardial infarction. Nature (1975) 1.07
Ventricular arrhythmias associated with coronary artery occlusion and reperfusion in the isolated perfused rat heart: a model for assessment of antifibrillatory action of antiarrhythmic agents. Cardiovasc Res (1978) 1.04
Experimental myocardial infarction with left ventricular failure in the isolated perfused rat heart. Effects of isoproterenol and pacing. J Mol Cell Cardiol (1975) 1.04
A relationship between adenosine triphosphate, glycolysis and ischaemic contracture in the isolated rat heart. J Mol Cell Cardiol (1981) 1.02
Combined alpha- and beta-adrenoceptor antagonism with prazosin and oxprenolol in control of severe hypertension in pregnancy. N Z Med J (1981) 1.02
Chorea gravidarum associated with circulating lupus anticoagulant: successful outcome of pregnancy with prednisone and aspirin therapy. Case report. Br J Obstet Gynaecol (1983) 0.99
Cyclic adenosine monophosphate, ventricular fibrillation, and antiarrhythmic drugs. Lancet (1976) 0.96
Distribution of myocardial blood flow before and after coronary artery ligation in the baboon. Relation to early ventricular fibrillation. Cardiovasc Res (1974) 0.94
Adrenaline-induced "oxygen-wastage" and enzyme release from working rat heart. Effects of calcium antagonism, beta-blockade, nicotinic acid and coronary artery ligation. J Mol Cell Cardiol (1979) 0.94
Effect of glucose-insulin-potassium infusions on epicardial ECG changes and on myocardial metabolic changes after coronary artery ligation in dogs. Cardiovasc Res (1981) 0.91
The lupus-anticoagulant: clinical and obstetric implications. N Z Med J (1984) 0.90
Catecholamine-mediated arrhythmias in acute myocardial infarction. Experimental evidence and role of beta-adrenoceptor blockade. S Afr Med J (1979) 0.89
Influence of propranolol isomers and atenolol on myocardial cyclic AMP, high energy phosphates and vulnerability to fibrillation after coronary artery ligation in the isolated rat heart. Cardiovasc Res (1981) 0.89
Amiodarone in long term management of refractory cardiac tachyarrhythmias. N Z Med J (1981) 0.89
The role of cyclic adenosine monophosphate in adrenergic effects on ventricular vulnerability to fibrillation in the isolated perfused rat heart. J Clin Invest (1978) 0.89
Cyclic AMP as a determinant of vulnerability to ventricular fibrillation in the isolated rat heart. Cardiovasc Res (1976) 0.86
Lupus anticoagulant and pregnancy. Am J Obstet Gynecol (1985) 0.86
Early experimental myocardial infarction. Evaluation of histologic criteria and comparison with biochemical and electrocardiographic measurements. Arch Pathol Lab Med (1976) 0.85
Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement. N Z Med J (1979) 0.85
Amiodarone-induced torsades de pointes. Eur Heart J (1986) 0.84
Hypertension in pregnancy. Pathophysiology and management. Drugs (1984) 0.84
Extensive pulmonary embolism associated with lupus anticoagulant. N Z Med J (1985) 0.83
Cyclic A.M.P. and arrhythmias revisited. Lancet (1978) 0.83
Letter: Are free fatty acids arrhythmogenic? J Mol Cell Cardiol (1975) 0.83
Multiple serous effusions complicating pre-eclampsia. A case report. S Afr Med J (1978) 0.82
Modulation of myocardial cyclic AMP and vulnerability to fibrillation in the rat heart. Fed Proc (1983) 0.81
Renin in the diagnosis of renovascular hypertension. Activity in renal and peripheral vein plasma. JAMA (1967) 0.80
Intracardiac thrombus in systemic lupus erythematosus associated with lupus anticoagulant. Arthritis Rheum (1988) 0.80
Amiodarone: its side effects, adverse reactions and dosage schedules. N Z Med J (1982) 0.79
Metabolic basis of increased vulnerability to fibrillation in myocardial ischaemia. J Mol Cell Cardiol (1987) 0.78
Beneficial effect of labetalol in hypertensive patients with angina pectoris. S Afr Med J (1983) 0.78
Antiphospholipid antibodies and pregnancy. N Engl J Med (1985) 0.78
Role of glycolytic flux in effect of glucose in decreasing fatty-acid-induced release of lactate dehydrogenase from isolated coronary ligated rat heart. Cardiovasc Res (1979) 0.78
Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol. Br J Clin Pharmacol (1982) 0.78
Q fever endocarditis: a report of 2 cases. S Afr Med J (1978) 0.77
Labetalol in hypertensive patients with angina pectoris: beneficial effect of combined alpha- and beta-adrenoreceptor blockade. Clin Sci Mol Med Suppl (1978) 0.77
Clinical usefulness of the beta-adrenergic antagonists. S Afr Med J (1978) 0.77
Glycolytic ATP and its production during ischemia in isolated Langendorff-perfused rat hearts. Recent Adv Stud Cardiac Struct Metab (1978) 0.77
Cardiac actions of adenosine. Methods Find Exp Clin Pharmacol (1984) 0.75
Corticosteroid treatment of pregnant women with antiphospholipid antibodies and previous fetal loss. Am J Obstet Gynecol (1990) 0.75
Evidence for role of cyclic AMP as second messenger of arrhythmogenic effects of beta-stimulation. Adv Cyclic Nucleotide Res (1980) 0.75
Antihypertensive treatment and fetal welfare in essential hypertension in pregnancy: a retrospective survey of experience with various regimes at National Women's Hospital, Auckland, 1970-80. N Z Med J (1982) 0.75
Serum myoglobin, creatine kinase and creatine kinase-MB as mutually supportive indices of myocardial infarction and infarct size. Aust N Z J Med (1982) 0.75
Antiarrhythmic actions of nifedipine in acute myocardial ischemia. Am Heart J (1983) 0.75
Antihypertensive therapy with timolol and alpha-methyldopa. A double-blind trial in patients with moderately severe hypertension. S Afr Med J (1976) 0.75
Permissive action of potassium on arrhythmogenesis in the rat heart. J Mol Cell Cardiol (1986) 0.75
More on beta-blockers in pregnancy. N Engl J Med (1982) 0.75
Psittacosis: a clinical spectrum in New Zealand. N Z Med J (1980) 0.75
Use of diltiazem during pregnancy. N Z Med J (1987) 0.75
The use of captopril in pregnancy. N Z Med J (1983) 0.75
Diuretics in pregnancy associated hypertension. N Z Med J (1983) 0.75
Clonidine in the management of uncontrolled hypertension. S Afr Med J (1974) 0.75
Hepatic and splenic haemorrhage as a complication of toxaemia of pregnancy in a patient with circulating lupus anticoagulant. N Z Med J (1982) 0.75
Renin and hypertension--a story of disillusionment. S Afr Med J (1978) 0.75
The management of hypertension in pregnancy. S Afr Med J (1981) 0.75
What has the baboon to offer as a model of experimental ischemia? Eur Heart J (1983) 0.75
Fluid compartments in hypertension. S Afr Med J (1978) 0.75
Antiarrhythmic action of labetalol and its effect on adenine metabolism in the isolated rat heart. J Am Coll Cardiol (1983) 0.75
Anticardiolipin antibodies: their presence as a marker for lupus anticoagulant in pregnancy. N Z Med J (1987) 0.75
Effect of substrate on enzyme release after coronary artery ligation in isolated rat heart. Recent Adv Stud Cardiac Struct Metab (1975) 0.75
Prazosin in the therapy of uncontrolled hypertension. S Afr Med J (1977) 0.75
Prostacyclin and maternal lupus anticoagulant. Lancet (1984) 0.75
World hypertension project, 1978. S Afr Med J (1978) 0.75
Economy in drug prescribing in Mozambique. Trop Doct (1980) 0.75
Long-term tolerance of amiodarone treatment for cardiac arrhythmias. Am J Cardiol (1986) 0.75
Catapres-TTS: a two year posttrial followup. N Z Med J (1988) 0.75
A community-based trial of transdermal antihypertensive therapy with clonidine (Catapres-TTS). N Z Med J (1986) 0.75